Results 221 to 230 of about 122,145 (339)

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the impact of scenario‐based multifactorial control on the 3‐year incidence of fatal/non‐fatal cardiovascular disease (CVD) and associated healthcare costs in Asian patients with type 2 diabetes (T2D). Materials and Methods We applied the validated ‘ABC’ model to simulate the 3‐year impact of attaining multiple treatment ...
Lee‐Ling Lim, Eric S. H. Lau, Juliana N. M. Lui, Linong Ji, A. G. Unnikrishnan, Sirinart Sirinvaravong, Siew‐Pheng Chan, Soo Lim, Andrea O. Y. Luk, Juliana C. N. Chan   +9 more
wiley   +1 more source

Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study. [PDF]

Health Aff Sch
Mattingly TJ, Duru EE, Conti RM.
europepmc   +1 more source

Glucocorticoid‐Induced Hyperglycaemia in Hospital: The Insulin Dose Matters Most

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Prescription of glucocorticoids in hospital is a common cause of new onset hyperglycaemia, which is associated with increased mortality and morbidity. However, to date studies have not defined optimal treatment of hyperglycaemia associated with glucocorticoids and this is reflected in clinical guidelines.
Morton G. Burt, Faran Khalili, Anjana Radhakutty, Angela X. Chen   +3 more
wiley   +1 more source

Impact of glucagon-like peptide-1 receptor agonists on colonoscopy outcomes: a systematic review and meta-analysis. [PDF]

Clin Endosc
Abdulraheem A, Abujaber B, Ayers L, Afzal U, Qarkash D, Altork N, Al-Zureikat Q, Bashiri K, Almhanni G, Spyros P, Cho WK.   +10 more
europepmc   +1 more source

Murine GLUTag Cells [PDF]

, 2015

core   +1 more source

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source

State‐Level Variation in Glucagon‐Like Peptide‐1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Tamkeen Khan, Stavros Tsipas, Fleetwood Loustalot, Lindsay Zasadzinski, Klodiana Myftari, Alyson B. Goodman, Gregory D. Wozniak   +6 more
doaj   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Knee Arthroplasty Outcomes. [PDF]

Indian J Orthop
Zaffar H, Imran MA, Rushd F.
europepmc   +1 more source

Cost‐Effectiveness of Control‐IQ+ Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE
Neda Al Rawashdh, Bimal V. Patel, Sharon M. Wang, Richard M. Zur, Pablo Anaya, Emily B. Kahn, Jordan E. Pinsker, Ravid Sasson‐Katchalski, Alex C. Trahan, Laurel H. Messer, Kimia Assadi, Yogish C. Kudva, Roy W. Beck   +12 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis. [PDF]

Cureus
Nashwan AJ.
europepmc   +1 more source